Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis

ABSTRACT

Introduction

Despite the availability of several treatments for psoriasis (PsO), factors influencing the persistence of secukinumab (SEC) therapy remain inadequately understood. This study aimed to identify predictors of SEC persistence in PsO.

Methods

A retrospective analysis was conducted on 109 PsO patients who received SEC treatment at least 1 year. Patients were categorized based on continued or discontinued SEC therapy.

Results

Among the 109 patients, 64 continued SEC treatment while 45 discontinued. Univariate analysis demonstrated that PsA presence and previous biologic therapy use increased the risk of SEC discontinuation 3.56- and 2.33-fold (p = 0.001, %95 CI: 1.66–7.65 and p = 0.032, %95 CI: 1.08–5.04, respectively). Additionally, the risk of SEC discontinuation is 57% higher in patients with a body mass index (BMI) above 26.5 compared to those with a BMI below 26.5 (p = 0.016, %95 CI: 0.22–0.85). Additionally, patients with PsO onset age below 26.5 years were found to have a 2.93-times higher risk of discontinuing SEC compared to those with PsO onset age above 26.5 years (p = 0.004, %95 CI: 1.40–6.13).

Conclusion

PsA presence, previous biologic therapy experience, BMI, and PsO onset age were identified as independent predictors of SEC discontinuation. These findings underscore the importance of personalized treatment strategies for PsO patients receiving SEC therapy.

KEYWORDS:

• Psoriasis
• secukinumab
• psoriatic arthritis
• body mass index
• biologics
• age onset of psoriasis

Declaration of interest

The authors have no conflict of interest to declare. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

N Akdogan and K Balan conceptualized and designed the study, and critically revised the manuscript. N Akdogan, K Balan, B Yalici-Armagan, D Gulseren, and S Dogan collected patient data and reviewed the manuscript. N Akdogan and K Balan performed the statistical analysis. N Akdogan drafted the manuscript and is the study guarantor.

Ethics statement

The study protocol was reviewed and approved by the Medical Ethics Committee of Hacettepe University (code GO 23/526, 20 June 2023) and all study procedures were made according to the ethical principles outlined in the 1975 Declaration of Helsinki and its subsequent amendment. Permission has been obtained from the dataset owner to utilize the information in the hospital database/repository for the purpose of conducting research. Since participants’ details are not required to be anonymized, written informed consent, including consent to publish, was obtained from participants.

Additional information

Funding

This paper was not funded.